about
Immunoreactivity of integrin-linked kinase in primary non-small-cell lung cancer and survival after curative resection.Concordance between epidermal growth factor receptor status in primary non-small-cell lung cancer and metastases: a post-mortem study.Randomized Trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study.Small sizes and indolent evolutionary dynamics challenge the potential role of P2RY8-CRLF2-harboring clones as main relapse-driving force in childhood ALL.Risk factors for diabetes insipidus in langerhans cell histiocytosis.Morphologic features of neuroblastoma (Schwannian stroma-poor tumors) in clinically favorable and unfavorable groups.Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study.Monocyte-mediated T-cell suppression and augmented monocyte tryptophan catabolism after human hematopoietic stem-cell transplantation.Variability of nm23-H1/NDPK-A expression in human lymphomas and its relation to tumour aggressivenessPrognostic impact of chromosomal aberrations in Ewing tumoursAntibiotic prophylaxis with teicoplanin on alternate days reduces rate of viridans sepsis and febrile neutropenia in pediatric patients with acute myeloid leukemia.Radiological features of thymic langerhans cell histiocytosis.High hyperdiploid acute lymphoblastic leukemia (ALL)-A 25-year population-based survey of the Austrian ALL-BFM (Berlin-Frankfurt-Münster) Study Group.Suppression of FOXO1 is responsible for a growth regulatory repressive transcriptional sub-signature of EWS-FLI1 in Ewing sarcoma.Treatment for soft tissue sarcoma in childhood and adolescence. Austrian results within the CWS 96 study.A multilocus technique for risk evaluation of patients with neuroblastoma.Induction death and treatment-related mortality in first remission of children with acute lymphoblastic leukemia: a population-based analysis of the Austrian Berlin-Frankfurt-Münster study group.Peripheral blood late mixed chimerism in leucocyte subpopulations following allogeneic stem cell transplantation for childhood malignancies: does it matter?Pulmonary involvement in pediatric-onset multisystem Langerhans cell histiocytosis: effect on course and outcome.Hemopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000-2010.Granulocyte transfusions in children and young adults: does the dose matter?Persistence and reactivation of human adenoviruses in the gastrointestinal tract.Screening for adenoviruses in haematological neoplasia: High prevalence in mantle cell lymphoma.Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial.Death induction by CD99 ligation in TEL/AML1-positive acute lymphoblastic leukemia and normal B cell precursors.Prognostic relevance of TLX3 (HOX11L2) expression in childhood T-cell acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Münster (BFM) protocols containing early and late re-intensification elements.2'-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). results of the LCH-S-98 protocol of the Histiocyte Society.A randomized trial of treatment for multisystem Langerhans' cell histiocytosis.Treatment outcome of CRLF2-rearranged childhood acute lymphoblastic leukaemia: a comparative analysis of the AIEOP-BFM and UK NCRI-CCLG study groups.Response to initial treatment of multisystem Langerhans cell histiocytosis: an important prognostic indicator.Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.Exhaled nitric oxide and pulmonary complications after paediatric stem cell transplantation.Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multicentric assessment is feasible.Blast cell deficiency of CD11a as a marker of acute megakaryoblastic leukemia and transient myeloproliferative disease in children with and without Down syndrome.Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification.Prevalence and clinical course of viral upper respiratory tract infections in immunocompromised pediatric patients with malignancies or after hematopoietic stem cell transplantation.Incidence and severity of crucial late effects after allogeneic HSCT for malignancy under the age of 3 years: TBI is what really matters.Treosulfan-based conditioning regimens for allogeneic haematopoietic stem cell transplantation in children with non-malignant diseases.Costs and cost-effectiveness of allogeneic stem cell transplantation in children are predictable.Central nervous system-related permanent consequences in patients with Langerhans cell histiocytosis.
P50
Q33542938-E3F98B2C-818A-4917-8B92-49E4BA6F0A5DQ33547754-5EC5BE94-E709-4C92-A520-C006449AD4C5Q34121964-EF01A852-BA27-4380-AAAA-7512AB0E2DB4Q34325528-FAD2F21C-788A-413C-8B52-5271B233355DQ34437480-8C263133-CD50-402E-8FC8-5AC97873478EQ34580464-E7D4B9CE-29C0-4F3B-8998-D7DCDED6E683Q34606771-9C6218D6-4B65-4001-89D1-4201128FBC65Q35847753-71B9AC93-AD3E-49E0-BB4F-431DB5203CC7Q36141262-F97E08DF-899E-4045-B863-0E58F831C5A5Q36644524-174C609F-D376-4D36-91D3-E37BD4B83454Q37579563-859AD0AB-C195-4F1C-A9BA-227107466A58Q38118281-1CB96058-75FF-4548-9778-764689DC098BQ38800499-60BF847E-87FA-4066-8A1B-E027207AA6BFQ39101609-5F435F75-D5AD-42A8-B7EF-D7ADE663757EQ39715775-C570DFA7-BB91-440B-BBF9-2A9BB7323842Q39782514-B1C6A837-F9E0-4D06-BA0F-304DB75A1F67Q39873557-FFFB5E4F-E1F1-4809-AB8D-DCBA4E74BB0DQ39903954-425882FE-1AFD-4E2D-B248-00152EB652D9Q40018416-50D623AF-8150-4CFA-A74A-D5D24E6C92C5Q40122851-B99944C3-24E6-4765-BB75-894529A95458Q40395707-1E117ED8-4BBB-4C4F-A200-01168B2EF26FQ40854484-EDFCDD72-6F6C-4706-B985-BA3C31649817Q42254781-D9A079B4-57EC-434E-BDFD-9240D45A11DAQ43023369-4905B6D5-CF0A-49EF-9584-4F1DD6E7C049Q43068913-83870E31-FC70-4F1E-948E-14BFF59FAC3AQ43263258-9B536539-28DE-46B3-A75C-D69B7C213D33Q43280895-4E497234-500A-4D8D-9415-EC541A7182C9Q43601136-1DB5A71D-ED7B-47E5-B5EA-E4D31DFCB4F5Q44077639-2A0271A6-8223-4F99-86EB-5F4F87609202Q44177471-FF22B810-1398-4F6A-8584-0A4F5B3AB002Q44438560-D8FDCC81-3281-481D-93CF-A172EB480CE7Q44459464-EB815BE3-01F6-4260-95B3-8061648CD8A5Q44501485-55069AD4-819B-4946-B640-71D366274925Q46145690-C95544F4-0681-4B67-944E-424DF1369E1CQ46843421-C6B405D0-9A9D-48B5-8FB0-E94755110779Q47414266-30EA286C-E656-420A-8503-CE935F59B250Q47959792-1370644A-D9F7-44CE-A036-78448474A8C0Q48148219-7A3CBAB6-F353-4D94-B46A-D7FB98E33F44Q48457773-1A39BA1B-4DD0-491E-8314-A20C49E485D5Q48654350-14B3B831-A6D4-4A85-B680-A66B60703E04
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ulrike Pötschger
@ast
Ulrike Pötschger
@en
Ulrike Pötschger
@es
Ulrike Pötschger
@nl
Ulrike Pötschger
@sl
type
label
Ulrike Pötschger
@ast
Ulrike Pötschger
@en
Ulrike Pötschger
@es
Ulrike Pötschger
@nl
Ulrike Pötschger
@sl
prefLabel
Ulrike Pötschger
@ast
Ulrike Pötschger
@en
Ulrike Pötschger
@es
Ulrike Pötschger
@nl
Ulrike Pötschger
@sl
P106
P21
P31
P496
0000-0001-7024-7082